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Abstract
Background: Whether vexing clinical decision-making dilemmas can be partly addressed by recent advances in genomics is
unclear. For example, when to initiate highly active antiretroviral therapy (HAART) during HIV-1 infection remains a clinical
dilemma. This decision relies heavily on assessing AIDS risk based on the CD4
+ T cell count and plasma viral load. However, the
trajectories of these two laboratory markers are influenced, in part, by polymorphisms in CCR5, the major HIV coreceptor, and
the gene copy number of CCL3L1, a potent CCR5 ligand and HIV-suppressive chemokine. Therefore, we determined whether
accounting for both genetic and laboratory markers provided an improved means of assessing AIDS risk.
Methods and Findings: In a prospective, single-site, ethnically-mixed cohort of 1,132 HIV-positive subjects, we determined
the AIDS risk conveyed by the laboratory and genetic markers separately and in combination. Subjects were assigned to a
low, moderate or high genetic risk group (GRG) based on variations in CCL3L1 and CCR5. The predictive value of the CCL3L1-
CCR5 GRGs, as estimated by likelihood ratios, was equivalent to that of the laboratory markers. GRG status also predicted
AIDS development when the laboratory markers conveyed a contrary risk. Additionally, in two separate and large groups of
HIV
+ subjects from a natural history cohort, the results from additive risk-scoring systems and classification and regression
tree (CART) analysis revealed that the laboratory and CCL3L1-CCR5 genetic markers together provided more prognostic
information than either marker alone. Furthermore, GRGs independently predicted the time interval from seroconversion to
CD4
+ cell count thresholds used to guide HAART initiation.
Conclusions: The combination of the laboratory and genetic markers captures a broader spectrum of AIDS risk than either
marker alone. By tracking a unique aspect of AIDS risk distinct from that captured by the laboratory parameters, CCL3L1-
CCR5 genotypes may have utility in HIV clinical management. These findings illustrate how genomic information might be
applied to achieve practical benefits of personalized medicine.
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Introduction
The last few years have witnessed an unprecedented interest
and effort in identifying the genetic determinants that underlie
susceptibility to human diseases. Concurrently there is strong
interest in developing ways to use this genetic information to
provide ‘‘individualized medicine’’, i.e., tailor the clinical care of
patients according to specific elements of their genetic constitution
that can convey independent predictive capacity with respect to
disease prognostication. However, a framework of how to assess
fully whether such genetic information might help improve the
clinical management of patients remains unclear, especially when
compared to laboratory markers that are considered the gold
standard in evaluating disease prognosis. To address this gap in
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encoding CC chemokine receptor 5 (CCR5), the major coreceptor
for HIV-1 [1], and CC chemokine ligand 3-like 1 (CCL3L1), the
most potent CCR5 agonist and HIV-suppressive chemokine
[2,3,4,5], and (iii) the laboratory markers (CD4
+ T cell count
and viral load) currently used to evaluate HIV-infected patients, as
a model system.
HIV-1-infected subjects are typically started on highly active
antiretroviral therapy (HAART) when their CD4
+ T cell count
reaches a threshold below which their risk for developing AIDS
increases significantly [6,7,8,9]. These HAART-initiating CD4
+ T
cell count thresholds vary depending on the clinical and economic
settings, but are typically between 200 and 350 CD4
+ T cells/mm
3
[6,7,8,9]. Nevertheless, when to initiate HAART in HIV-infected
subjects remains a clinical dilemma [10,11], especially when
individuals present for clinical care with CD4
+ T cell counts above
350. Those favoring early initiation cite, among other reasons, the
risk that progressive immunologic damage will be incompletely
reversible after initiation of HAART [10]. However, there are
significant inter-subject differences in the rate at which individuals
lose and gain CD4
+ T cells before and after receipt of HAART,
respectively. Consequently, identifying subjects who, despite
HAART, are at greater risk of persistent immunologic damage,
or predicting how soon an HIV-infected individual might arrive at
a predetermined HAART–initiating CD4
+ T cell count poses a
diagnostic challenge. Furthermore, although a CD4
+ T cell count
and plasma viral load provides an excellent snapshot of the
immunological and virological status of the infected host at the
time of their clinical assessment, they are imperfect surrogates of
AIDS risk. This is because both reside downstream of the causal
pathways that mediate the extent of CD4
+ cell loss and viral
replication [12,13], and hence, they do not have any inherent
capacity to predict their future trajectory. This necessitates serial
determinations of these biomarkers to assess AIDS prognosis.
The trajectories of CD4
+ T cell counts before and during
HAART are likely to be dependent on host-viral interactions
[14,15,16,17,18,19,20,21,22,23,24,25,26]. Additionally, during
HAART these trajectories are also likely to depend in part on
the regenerative capacity of the host as up to 30% of HIV-infected
subjects have impaired recovery of CD4
+ T cell counts, despite
suppression of viral replication [27,28,29]. Additionally, a large
proportion of patients who initiate therapy with a low CD4
+ nadir
(,200 cells/mm
3) fail to normalize CD4
+ counts, despite HIV-
suppressive HAART [27,29,30,31,32,33,34,35]. Thus, accounting
for polymorphisms in host genes that participate in causal host-
viral interactions that affect CD4
+ T cell depletion before HAART
and the immune reconstitution (i.e., recovery of CD4
+ T cell
numbers and function) during HAART might provide a measure
of genetic risk that could aid in the clinical assessment and
management of HIV-infected subjects. Conceivably, those subjects
whose genetic constitution confers a greater risk of progressing
rapidly to AIDS as well as impaired recovery during HAART
might benefit from earlier initiation of therapy and possibly also
from adjuvant therapies that promote immunological recovery
(e.g. recombinant IL-7 [36]).
In this study, we focused on evaluating the prognostication
capacity of genetic variations in CCR5 and CCL3L1 vis-a `-vis the
laboratory markers for the following reasons. There is substantial
data demonstrating that polymorphisms in CCR5 are associated
with variable susceptibility to HIV, AIDS progression rates, and
CD4
+ T cell count recovery during HAART [14,15,16,17,18,
19,20,21,22,23,37,38,39,40,41]. The copy number of CCL3L1
influences mRNA/protein expression levels of this potent HIV
suppressive chemokine [2,5] as well as proportion of CD4
+ T cells
expressing CCR5 [5,42], and CCL3L1 gene dose has been
associated with intersubject differences in (i) susceptibility to
HIV acquisition in European-, African-, Hispanic-American
adults, intravenous drug users from Estonia and hemophiliacs
from Japan [5,43,44], as well as children exposed perinatally to
HIV-1 from Argentina and South Africa [5,45,46]; (ii) viral load in
different cohorts, including subjects who were recruited during
acute/early infection as well as HIV
+ women from South Africa
[5,20,45,47]; (iii) rates of progression to AIDS in European and
African Americans [5]; (iv) HIV-specific CD4
+ and CD8
+ T cell
responses [47]; and (v) recovery of CD4
+ T cell counts in subjects
who received HAART during chronic or acute/early HIV
infection [23]. Additionally, we found that CCL3L1 copy number
and CCR5 genotypes that were associated with reduced cell
mediated immune responses in HIV-negative individuals of
European descent were similar to those that were associated with
a rapid rate of disease progression in HIV
+ European Americans
[20], suggesting that the CCL3L1-CCR5 axis might play an
important role in mediating cellular immune responses relevant to
AIDS pathogenesis. In the latter analyses, cell mediated immune
responses in HIV-negative subjects was assessed by delayed type
hypersensitivity (DTH) skin test reactivity following challenge with
two separate antigens namely keyhole limpet hemocyanin and
purified protein derivative, and concordant associations were
observed with both antigens ([20]; DTH responses are an in vivo
parameter of T cell and cell mediated immune responses, and the
strength of DTH responses are an independent determinant of
AIDS susceptibility [20,48,49,50,51,52,53]). Finally, the finding
that copy number variation in CCL3-like genes is also present in
chimpanzee [5], macaque [54] and other non-human primate
species (our unpublished observations) suggests an evolutionarily
conserved host defense function for CCL3L-like genes in humans
and non-human primates.
To evaluate the genotype-phenotype associations for the
combined effects of variations in CCL3L1 and CCR5, we assigned
subjects to low, moderate and high CCL3L1-CCR5 genetic risk
groups (GRGs), defined according to different combinations of
specific CCR5 polymorphisms and CCL3L1 gene copy number
[5,20]. A low, moderate and high CCL3L1-CCR5 GRG status was
associated with a step-wise increase in susceptibility to depletion of
CD4
+ T cells during HIV-1 infection, as well as impaired CD4
+ T
cell recovery during HAART [20,23]. The association between
CCL3L1-CCR5 GRG status and CD4
+ T cell loss and/or AIDS
susceptibility was observed in two separate groups of subjects who
were followed from the early stages of their infection within the
context of a natural history cohort as well as in a separate cohort of
subjects who were recruited during acute/early infection
[5,20,23]. Furthermore, we observed an enrichment of protective
CCL3L1-CCR5 genotypes in subjects from a natural HIV-1 history
cohort who were AIDS-free for more than 10 years, as well as in
individuals from two different cohorts who were categorized as
spontaneous HIV-1 controllers, i.e., elite or viremic controllers
[20,55], further underscoring that these genetic factors might play
an important role in restricting disease progression. The
association between CCL3L1-CCR5 GRG status and immune
recovery was assessed in subjects who received HAART during
chronic infection using two separate phenotypic endpoints: CD4
+
T cell count [23] and function [20], assessed by DTH skin test
responses. Concordant associations between CCL3L1-CCR5 geno-
type and recovery of CD4
+ T cell counts were also observed in
subjects who received HAART during acute/early infection [23].
Collectively, these findings suggested that CCL3L1-CCR5 genetic
markers may have dual prognostic capacities, i.e., for both CD4
+
T cell loss and recovery. A possible role for these genetic markers
CCL3L1-CCR5 in AIDS Prognosis
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that CCL3L1-CCR5 GRG status predicted HIV disease course
independent of the viral load and CD4
+ T cell count as well as
other explanatory variables that were in themselves independent
markers of disease progression (e.g., percent, nadir and cumulative
CD4 cell counts, and DTH skin test reactivity) [20]. Notably, the
latter associations were observed in two separate and large groups
of subjects who within the context of a natural HIV-1 history
cohort were followed prospectively from the early stages of their
infection [20]. These findings suggested that there is a component
of AIDS risk that is genetically-defined by CCL3L1-CCR5 genetic
variations which may not be captured fully by the laboratory
markers. The consistency of the disease-influencing associations
for CCL3L1-CCR5 GRG status that were independent of viral load
and CD4
+ T cell count as well as other explanatory variables in
two separate groups of HIV-positive subjects prompted us to
examine whether CCL3L1-CCR5 genetic factors might have utility
in the clinical management of HIV-infected subjects.
For CCL3L1-CCR5 GRG status to have utility in the clinical
management of HIV, in addition to an influence of CCL3L1-CCR5
genotypes on CD4
+ cell recovery during HAART, we surmised
that the following four criteria would have to be met. First, the
prognostic strength of the GRGs for rates of disease progression
should be comparable to that of the CD4
+ cell count and plasma
HIV viral load, contemporary laboratory markers used to assess
AIDS prognosis in HIV-positive patients. Second, GRG status
should accurately predict an increased risk of developing or
progressing rapidly to AIDS when the laboratory markers may fail
to do so. Third, the AIDS risk conveyed by the laboratory and
genetic markers together, namely the CD4
+ T cell count plus viral
load plus GRG status, should exceed that conveyed by the two
laboratory markers, especially during the early stages of infection
when subjects have high CD4
+ T cell counts. Fourth, GRG status
should serve as independent determinants of the time interval from
seroconversion to CD4
+ cell count thresholds that are used to
guide initiation of HAART. Here, in a large, well-characterized
cohort of HIV-1-infected subjects, we investigated whether
CCL3L1-CCR5 GRG status met each of these criteria. The sum
of our findings using different analytical approaches suggests that
the CCL3L1-CCR5 GRG status meet these criteria. These findings
have broader translational value as they indicate that AIDS risk is
an individual characteristic that might be estimated with an
increased level of confidence if one also considers the genetic
make-up of the host.
Methods
Study cohort
In this study, we used the copy number of CCL3L1 gene [5] and
CCR5 genotype data [5,18] from a cohort of adult HIV
+ subjects
followed at the Wilford Hall United States Air Force Medical
Center (WHMC), San Antonio, TX. This prospective observa-
tional cohort is a component of the United States Military’s Tri-
Service AIDS Clinical Consortium (TACC) Natural History Study
[20,23]. The characteristics of the study subjects (n=1,132) have
been described extensively previously [5,18,56,57] and are
summarized in Table S1. The nature of the WHMC HIV
+
cohort is such that both the seroconverting and seroprevalent
groups of patients were followed prospectively from the time of
their diagnosis during the early stages of their disease, albeit the
approximate time of seroconversion was estimable only in the
former group. However, consistent with this recruitment pattern
during the early stages of their disease we found that the genotype-
phenotype associations detected in these two groups of patients
were very similar [20]. For this reason, in this study relevant
findings detected in the seroconverters (n=515) were validated in
the seroprevalent (n=617) component of the cohort. Forty percent
of the entire cohort progressed to AIDS (1987 criteria), and 39%
died during the study period that ended December 31, 1999.
Thus, this cohort was well suited to evaluate our study questions/
criteria because all subjects were prospectively followed from the
early stages of their infection, and factors that may confound
genotype-phenotype studies (e.g., unequal access to medical care
and antiretroviral therapy, and loss to follow-up) were not present
[5,20,23]. The voluntary, fully informed consent of the subjects
used in this research was obtained as required by Air Force
Regulation 169-9 and additional approval from the Institutional
Review Board (IRB) of WHMC and the University of Texas
Health Science Center, San Antonio, TX.
CCL3L1-CCR5 Genetic Risk Groups
The copy number of CCL3L1 [5] and CCR5 haplotype pairs
were categorized into three risk categories, and we labeled a
patients’ CCL3L1-CCR5 genotype as a low, moderate or a high
GRG. The prevalence of the low (CCL3L1
highCCR5
non-det), moder-
ate (CCL3L1
highCCR5
det and CCL3L1
lowCCR5
non-det) and high
(CCL3L1
lowCCR5
det) GRG in the WHMC cohort is 50, 42, and
8%, respectively [5,20]. In some analyses, we combined the
moderate and high GRG into a single category. Of the 1,132 study
subjects, CCL3L1-CCR5 genotype data for this study was available
from 1,103 HIV
+ subjects and they were 624, 410 and 69
European-, African- and Hispanic-Americans, respectively [5].
Clinical outcomes and laboratory parameters
The outcomes analyzed were risk of development of AIDS, and
rate of progression to AIDS as well as to CD4 cell count thresholds
used to guide initiation of HAART [6,7,8,9]. The 1987 Centers
for Disease Control (CDC) criteria for AIDS were used in these
studies. The laboratory variables studied were baseline CD4 cell
counts, steady-state viral load, and DTH skin test responses. DTH
responses reflects T cell function in vivo (e.g. IL-2 production) and
is an independent predictor of disease outcome [20,50,51,52].
Extensive details regarding the DTH testing are provided
elsewhere [20,52].
As described previously [20,58], we accounted for possible
receipt of anti-retroviral therapy (ART) by using the calendar year
of membership in the cohort as a proxy for receipt of mono/dual
therapy (1990–1996) and HAART (1996-onwards). All subjects
who were recruited in the therapy eras were pooled into a single
group [20]. The therapy eras and the number of subjects with
cohort membership during each era are as described previously
[20]. Predictably, membership of a subject to the era in which
HAART was available was associated with a significantly reduced
risk of progressing to AIDS [20].
Statistical methods
To address our study questions/criteria, we used the following
statistical approaches.
First, to determine whether the CCL3L1-CCR5 GRGs conveyed
a reduced or increased AIDS risk in settings when the laboratory
markers would have suggested an opposite risk, we employed the
likelihood ratio (LR) statistic. We used this statistic as it more
directly describes the effect of a test result (in this case GRG status)
on the odds of disease [59]. LR estimates for the possibility of
developing AIDS in the future based on the stratum of the
laboratory markers as well as for the low, moderate and high
GRGs. The stratum for the baseline CD4 cell counts were ,350,
350–699, or $700 cells/mm
3, and for the viral load they were
CCL3L1-CCR5 in AIDS Prognosis
PLoS ONE | www.plosone.org 3 September 2008 | Volume 3 | Issue 9 | e3165, or $55,000 copies/ml. These cut-offs were based on published
guidelines for assessing AIDS risk that were prevalent during the
time these analyses were being conducted. LR was estimated as
the ratio of the incidence of AIDS in subjects with a given GRG,
CD4 or viral load stratum (i.e., post-test probability of developing
AIDS in the study cohort based on the laboratory or genetic
markers) and the overall incidence of AIDS in the entire cohort
(i.e., pre-test probability of AIDS in the study cohort before
accounting for the laboratory or genetic markers). Thus, the LR
represents an altered risk in the possibility of developing AIDS in
the future based on a subjects’ GRG and specific stratum of CD4
or viral load (or the indicated combinations thereof) divided by the
overall likelihood of developing AIDS in the HIV
+ subjects in the
WHMC cohort during the study period.
Second, in addition to the LR, we also estimated the pre- and
post-test probabilities of developing AIDS during the study period.
The LR and probabilities of developing AIDS during the study
period were assessed at twolevels:weinitially calculated LRs and the
pretest probability for the laboratory and genetic markers separately
(unstratified analysis), and then in the different CD4 and viral load
strata in subjects with specific GRGs (stratified analyses).
Third, using a Poisson regression model, we estimated the annual
incidence of AIDS in the seroconverting component of the WHMC
cohort according to a subjects’ laboratory and genetic markers.
Fourth, we derived an estimate of the number of subjects one
would need to treat to prevent the occurrence of one case of AIDS
(that is, the number-needed-to-treat, NNT). For this, we applied
separate Poisson regression models to data from seroconverters
who were recruited in eras when antiretroviral therapy (ART) was
available (therapy era) or was not available (no therapy era). From
these results, the NNT was calculated as follows: If In and It
represent the estimated incidence of AIDS in the no therapy era
(n) and therapy (t) era from the Poisson regression models,
respectively, then NNT=1/(In2It). The estimate of NNT
obtained was then rounded to the nearest integer.
Fifth, we used two distinct yet complementary approaches to
assess whether the GRGs provided additive value for prognosti-
cation of AIDS over and above that provided by the CD4 cell
count and viral load. In the first approach, we used a risk scoring
system based on cut-offs for CD4 cell counts and the viral load,
and conducted survival analyses for time to AIDS. The cut-offs
used were based on CD4 cell count and viral load thresholds at
which one might consider initiation of therapy. In the risk scoring
systems, the cut-offs for CD4 cell counts were at 200, 350 and
450 cells/mm
3 and for the viral load it was at 55,000 copies/ml; a
CD4 cell count of 450 cells/mm
3 was used as a threshold to
determine the relative prognostic value of the laboratory and
genetic markers during the early stages of the infection and was an
arbitrary cut-off used to reflect early stage disease. Kaplan Meier
(KM) survival curves were constructed to graphically illustrate the
rate of progression to AIDS, and the log-rank test was used for
between-group analysis. We used Cox proportional hazards
models to estimate the relative hazards (with 95% confidence
intervals (CI)) after testing for the assumption of proportional
hazards by plotting the Schoenfeld residuals. Schoenfeld residuals
were calculated for each Cox proportional hazards model studied
by using the Breslow-Peto approach. Model fit was assessed using
the likelihood ratio chi-square (LR x
2) and Akaike information
criterion (AIC). The critical x
2 was estimated by dividing the
logrank x
2 by its degrees of freedom. The risk-scoring systems were
first applied to the seroconverting component of the cohort and
then for purposes of replication, we also estimated the LR x
2 and
AIC estimates in the seroprevalent group of subjects in the
WHMC cohort. In the second risk-scoring approach, we used the
classification and regression trees (CART) that are commonly used
as a method of deductive reasoning for the purposes of data
mining and extracting relationships among the predictor variables
[60,61,62,63,64]. The advantage of the CART approach is that
the algorithm generates a decision-tree that is free of any
preconceived bias with respect to predefined cut-offs for viral
load and CD4 cell counts at which ART might be initiated. The
decision tree generated by CART for risk of developing AIDS was
then used to determine whether it also had applicability for
stratifying the rate of progression to AIDS. Extensive details of the
model are provided in Section 1 of the Text S1 and Figure S1.
Finally, KM survival curves were used to determine time-from-
seroconversion to the CD4 cell count thresholds that might be
used to decide when to initiate HAART. We used the thresholds of
200 and 350 as well as 450 cells/mm
3. We used Stata 7.0 (Stata
Corp., College Station, TX) software for all statistical analyses and
the program DTREG (Brentwood, TN) for generation of the
classification trees.
Results
The four criteria that might provide a framework for
considering CCL3L1-CCR5 GRG status in the clinical manage-
ment of HIV-infected subjects were addressed as follows.
Criterion one
To determine whether the genetic and laboratory markers had
comparable prognostic capacities, we first conducted unstratified
analyses in which we computed the probabilities and likelihood ratio
(LR) of developing AIDS based on a subject’s baseline CD4 or
steady-state viral load stratum before accounting for that person’s
GRG. Similar estimates for the GRGs were computed before
accounting for a subject’s CD4 or viral load (Table 1). The pretest
probability of developing AIDS in the entire cohort and the
seroconverting component of the cohort in whom CCL3L1-CCR5
genotype wasdeterminedwas39%and27%,respectively.However,
the post-testprobabilities of developing AIDS differed according to a
person’s GRG or CD4 cell count (Table 1). Notably, in the overall
cohort, the posttest probabilities (parenthesis) for a low (32%),
moderate (43%), and high (66%) GRG were similar to those for a
baseline CD4 cell count of $700 (26%), 350–699 (40%) and ,350
(61%) cells/mm
3 (Table 1; values in parentheses denote the posttest
probabilities,and for GRG status they are the estimatesshowninthe
bottom-mostrowofTable1,whereasfortheCD4cellcounttheyare
the estimates shown under the column ‘‘unstratified by GRG’’).
AL Ro f.1o r,1 indicates a greater or lower likelihood of
developing AIDS, respectively, and we found that the three CD4
and viral load strata as well as a low, moderate and high GRG status
were each associated with predictable LRs (Table 1). For example,
LRs for a low, moderate and high GRG were 0.73, 1.16, and 3.02,
respectively(Table1,bottom-mostrow). The LRestimatesfor a low,
moderate and high GRG were quantitatively very similar to the LRs
(estimates in parenthesis) for a baseline CD4 cell count of $700
(0.55), 350–699 (1.04) and ,350 (2.44) cells/mm
3 (the latter
estimates are in the column denoted as ‘‘unstratified by GRG’’ in
Table 1). Similarly, the LR (parenthesis) for a low (0.73) and high
(3.02) GRG were similar to those for a viral load of ,55,000 (0.74)
and $55,000 (2.22) copies/ml, respectively (the latter estimates are
in the column ‘‘unstratified by GRG’’ in Table 1). Thus, the results
of these unstratified analyses indicated that the posttest probabilities
and LR estimates of developing AIDS associated with a low,
moderate or high GRG were remarkably similar to those conveyed
by strata of laboratory markers that are known to prognosticate a
low, moderate or high risk of AIDS.
CCL3L1-CCR5 in AIDS Prognosis
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However, because a low, moderate and high GRG status
associate with different degrees of CD4 cell loss and viral
replication, an argument could be made that the GRGs do not
add any additional prognostic information than that conveyed by
the laboratory markers. Thus, we sought to determine whether
GRG status predicted risk of AIDS when the CD4 and viral load
may not. For this, we conducted stratified analyses in which we
computed the LRs for the CD4 and viral load strata but after
accounting for a subject’s GRG (Table 1, columns under
‘‘stratified by GRG’’). Three examples are used to illustrate that
GRG staus accurately conveyed a reduced or increased AIDS risk,
even in instances when the laboratory markers in themselves
would have predicted a contrary risk of developing AIDS (Table 1).
First, the LR and posttest probability values for a CD4 cell count
of ,350 cells/mm
3 were 2.44 and 61%, respectively, but for a
low, moderate, or high GRG in this CD4 strata they were 0.69
and 52%, 1.01 and 62%, and 13.3 and 95%, respectively (Table 1,
top row). Hence, among subjects in whom a low CD4 count
predicted an increased likelihood of developing AIDS, a low GRG
tracked a subset of these subjects who have a lower risk of
developing AIDS, whereas a high GRG identified a subset of
individuals in this vulnerable CD4 cell stratum of ,350 cells/mm
3
who have an even higher risk of developing AIDS.
Second, the LR and posttest probability values for a CD4 cell
count of $700 cells/mm
3 were 0.55 and 26%, respectively; but
for a low, moderate, or high GRG within this CD4 stratum they
were 0.70 and 20%, 1.35 and 32%, and 2.40 and 46%,
respectively (Table 1). In this instance, among subjects in whom
a high CD4 count would have predicted a lower likelihood of
developing AIDS, a high and moderate GRG identified subsets of
subjects with increased likelihoods of developing AIDS. Third, in
the seroconverting subjects, the LR and posttest probability values
for a CD4 cell count of $350 cells/mm
3 and a viral load of
,55,000 copies/ml were 0.64 and 19%; these values were 0.70
and 14%, 1.27 and 23%, and 3.28 and 43% for those assigned to a
low, moderate, or high GRG, respectively (Table 1, estimates
shown under row entitled ‘‘CD4 plus viral load’’). Results of these
analyses indicated that knowledge of the CCL3L1-CCR5 GRG
status may improve the ability to predict AIDS risk, especially by
identifying those subjects whose CD4 and viral load parameters
may incorrectly predict a contrary risk of developing AIDS.
Criterion three: approach #1 – risk-scoring systems
To determine whether GRG status added to the prognostic
capacity of the CD4 cell count and viral load in predicting the risk
of developing AIDS in seroconverters, the CD4 cell count and
viral load were stratified as shown in Table 2. Predictably, the
incidence of AIDS was much greater in those subjects whose
membership in the cohort did not coincide with the therapy era
(range: 4.3 to 52.3) than in those whose membership in the cohort
coincided with the therapy era (range: 1.1 to 19.6; Table 2).
However, irrespective of therapy eras, within each CD4/viral load
stratum, low, moderate and high GRG status conveyed a step-wise
increase in AIDS risk, which was also evident among subjects with
the lowest risk CD4 cell count ($700 cells/mm
3) and viral load
(,20,000 copies/ml) profile (Table 2). Based on these analyses, we
determined the number of patients that one would need to treat
with HAART to prevent one case of AIDS if the GRG status of
the patient were accounted for (Table 2). These analyses suggested
that in each CD4/viral load stratum, compared to those with a
high GRG, twice the number of subjects with a low GRG would
need to be treated to prevent one case of AIDS (Table 2).
The preceding findings underscored that over and above the
AIDS risk conveyed by the CD4 cell count and viral load,
CCL3L1-CCR5 GRG status may serve as a unique parameter to
identify HIV-infected individuals who are at an increased risk of
developing AIDS. To investigate further this possibility, we
Table 1. The likelihood ratio (LR) and pre- and post-test probability of developing AIDS according to the laboratory markers and
CCL3L1-CCR5 GRGs.
Unstratified by GRG Stratified by GRG
Low GRG Moderate GRG High GRG
CD4 or Viral load strata N
LR (95% CI) [pre-test,
post-test]
LR (95% CI) [pre-test,
post-test]
LR (95% CI) [pre-test,
post-test]
LR (95% CI) [pre-test,
post-test]
CD4+ T cells (cells/mm
3)*
,350 186 2.44 (1.87–3.19) [39%, 61%] 0.69 (0.51–0.93) [61%, 52%] 1.01 (0.71–1.45) [61%, 62%] 13.3 (1.83–96.3) [61%, 95%]
$350 916 0.83 (0.78–0.88) [39%, 35%] 0.74 (0.64–0.86) [35%, 28%] 1.22 (1.04–1.42) [35%, 40%] 2.34 (1.45–3.77) [35%, 56%]
350–699 566 1.04 (0.92–1.16) [39%, 40%] 0.78 (0.65–0.94) [40%, 34%] 1.12 (0.94–1.35) [40%, 43%] 2.23 (1.24–4.02) [40%, 60%]
$700 350 0.55 (0.45–0.67) [39%, 26%] 0.70 (0.54–0.91) [26%, 20%] 1.35 (1.03–1.78) [26%, 32%] 2.40 (1.03–5.60) [26%, 46%]
Viral load{
$55 k 95 2.22 (1.57–3.13) [27%, 45%] 0.73 (0.44–1.20) [45%, 37%] 1.06 (0.66–1.68) [45%, 46%] 2.33 (0.76–7.20) [45%, 66%]
,55 k 310 0.74 (0.64–0.87) [27%, 22%] 0.69 (0.51–0.93) [22%, 16%] 1.31 (0.96–1.81) [22%, 27%] 3.19 (1.28–7.95) [22%, 47%]
CD4 plus viral load{
$350 and ,55 k 270 0.64 (0.52–0.79) [27%, 19%] 0.70 (0.50–0.97) [19%, 14%] 1.27 (0.88–1.83) [19%, 23%] 3.28 (1.28–8.39) [19%, 43%]
All subjects* 1103 0.73 (0.64–0.83) [39%, 32%] 1.16 (1.01–1.34) [39%, 43%] 3.02 (1.96–4.64) [39%, 66%]
The unstratified analyses are posttest and LR estimates for the baseline CD4
+ T cell count and steady-state viral load prior to accounting for a subject’s GRG and are in
the column denoted as ‘‘unstratified by GRG’’, whereas similar estimates for the GRGs before accounting for a subject’s baseline CD4 cell count and steady-state viral
load are in the bottom-most row.
*Data are for the entire cohort.
{Data are for seroconverting subjects and indicates the steady-state viral load in these subjects. k, denotes610
3 copies/ml.
The percentages in the brackets [ ] denote the pre-test followed by the post-test probability of developing AIDS.
doi:10.1371/journal.pone.0003165.t001
CCL3L1-CCR5 in AIDS Prognosis
PLoS ONE | www.plosone.org 5 September 2008 | Volume 3 | Issue 9 | e3165considered whetherGRGsandlaboratorymarkers canbecombined
in a clinically meaningful way to enhance AIDS prognostication. As
riskscoring systemshaveaninherent ease ofapplicabilityina clinical
setting, we used this as an approach to evaluate whether the
prognostic value of GRGs might have value in clinical practice. We
determined whether a three-pronged risk-scoring system that
included the two laboratory markers and GRG status was superior
in fractionating the risk of progressing rapidly to AIDS when
compared to a two-pronged risk-scoring system that excluded GRG
status. The first scoring system stratified the seroconverting
component of the cohort into two groups based on whether their
baseline CD4 cell count was , or $200 cells/mm
3 (Figure 1A, and
B to E); the second scoring system used a CD4 cut-off of 450 cells/
mm
3 but excluded the subjects with ,200 CD4-cells/mm
3
(Figure 1A and F to I); and the third scoring system also used a
cut-offof450 cells/mm
3butexcludedthosewithaCD4cellcountof
,350 cells/mm
3 (Figure 1A and J to M). By excluding subjects with
CD4 counts of ,200 or ,350 and by placing the upper CD4 cell
count threshold at 450 cells/mm
3, the second and third risk-scoring
systems offered the opportunity to explore whether GRG status can
prognosticate AIDS risk during the earlier stages of the disease, i.e.,
when the baseline CD4 cell count is higher.
In each of the three risk-scoring systems tested (Figure 1, B to D,
F to H, and J to L), the prognostic performance of the nested
models and survival curves that contained GRG status along with
the CD4 and viral load (i.e., C+V+G) were superior to those risk-
scoring systems that excluded the GRGs (i.e., C+V). Concordant
effects of the GRGs were also found in the seroprevalent
component of the cohort (Figure 1, E, I and M). The additive
prognostication conveyed by the GRGs was indicated by (i) the
Kaplan-Meir (KM) plots in which the disease-modulating effects of
the GRGs were accounted for displayed improved stratification for
different rates of disease progression than those plots in which only
the effects of CD4 cell count and viral load were accounted for; (ii)
higher critical x
2 values for the Cox models that contained the
GRGs (values are in the panels depicting the KM plots; e.g.,
compare critical x
2 of 0.84 and 10.05 in panels J and K in models
lacking and containing the GRGs, respectively); and (iii) higher
likelihood ratio x
2 and lower AIC values in models that included
the GRGs (Figure 1, panels D–E, H–I, L–M).
The KM plots showed that the CD4 cell count and viral load
provided the most prognostication only in the first scoring system,
i.e., when subjects with a CD4 of ,200 cells/mm
3 were included
in the model (Figure 1, compare panel B versus panels F and J).
Supporting this, the prognostic capacity of the CD4 cell count as
reflected by the estimates for the likelihood ratio x
2 and AIC were
most apparent in subjects with a CD4 count of ,200 cells/mm
3
(Figure 1, D and E), but negligible in the other two scoring systems
in which the CD4 cell counts were .200 cells/mm
3 (Figure 1, H,
I, L and M). Notably, in the second and third risk-scoring systems,
the values for the likelihood ratio x
2 and AIC were similar for the
viral load and the GRGs (Figure 1, H, I, L and M), suggesting that
the prognostic information conveyed by the viral load and GRG
status in these two risk-scoring systems were comparable.
Criterion three: approach #2 – CART analysis
The predefined cut-offs for CD4 cell counts and the viral load in
a risk-scoring system is useful because they reflect thresholds
currently used to decide the initiation of HAART (e.g., CD4#200
or 350 cells/mm
3). However, the use of these cut-offs has the
Table 2. Annual incidence of AIDS (%) and numbers needed-to-treat according to baseline CD4
+ T cell count, the steady-state viral
load and CCL3L1-CCR5 GRG, based on Poisson regression model.
GRG CD4$700 CD4 350–699 CD4,350
Viral load Viral load Viral load
,20 k 20-,55 k $55 k ,20 k 20-,55 k $55 k ,20 k 20-,55 k $55 k
Annual Incidence of AIDS
All patients (N=402)
Low 1.6 3.3 4.6 2.0 4.2 5.9 3.4 7.1 9.9
Moderate 2.3 4.7 6.6 2.9 6.0 8.3 4.9 10.1 14.1
High 4.8 9.8 13.7 6.0 12.4 17.3 10.2 20.8 29.1
Patients not in HAART era (N=97)
Low 4.3 7.3 11.9 4.8 8.1 13.3 8.8 15.0 24.5
Moderate 5.3 9.1 14.9 5.9 10.2 16.6 11.0 18.7 30.6
High 9.1 15.5 25.4 10.1 17.3 28.4 18.7 31.9 52.3
Patients in HAART era (N=305)
Low 1.1 2.1 2.4 1.5 2.9 3.2 3.6 6.9 7.7
Moderate 1.6 3.0 3.4 2.2 4.1 4.6 5.2 9.8 10.9
High 2.8 5.4 6.0 3.9 7.3 8.2 9.2 17.5 19.6
Numbers needed-to-treat
L o w 3 21 9 1 03 11 0 1 01 91 2 6
Moderate 27 16 9 26 16 8 17 11 5
High 16 10 5 16 10 5 11 7 3
Results are from the seroconverting component of the cohort. CD4 cell count (baseline) is in cells/mm
3. k, denotes610
3 copies/ml. The assignment of subjects whose
membership in the WHMC cohort fell in the eras in which HAART was available or not, and the impact of the HAART era on rates of disease progression are as described
previously [20].
doi:10.1371/journal.pone.0003165.t002
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improved discrimination of AIDS risk. For this reason, we used an
additional approach to address criterion 3 and assessed the role of
the GRGs in AIDS prognostication by using a classification and
regression tree (CART) approach (Figure 2A and Figure S1).
Based on the differential risk of developing AIDS, CART analysis
Figure 1. Prognostic performance of the CCL3L1-CCR5 GRGs in risk-scoring systems. Panel A shows the three risk-scoring systems based on
baseline CD4
+ T cell counts (C), viral load (V) and GRGs (G) in the seroconverting and separately in the seroprevalent component of the WHMC HIV
+
cohort. Panels B–C, F–G and J–K depict Kaplan Meier (KM) plots for progression to AIDS (1987 criteria) before and after accounting for the GRGs in the
risk-scoring systems indicated on the left axis. The critical ratio x
2 values are indicated within the KM plots. Panels D, H and L depict likelihood ratio x
2
and AIC estimates in seroconverters, and panels E, I and M depict the same estimates for the seroprevalent subjects.
doi:10.1371/journal.pone.0003165.g001
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+ cohort. (A) A binary decision
tree derived by CART analysis for the risk of developing AIDS (1987 criteria) based on baseline CD4
+ T cell counts, viral load (VL) and GRG status in the
seroconverting component of the WHMC HIV
+ cohort. The analysis identified five exclusive groups designated as Groups A to E. The tree shows that
the proximal split was based on the CD4 cell count, and the CART analysis generated the cut-off to be 453 cells/mm
3. The next split was based on a
viral load of 17,500 copies/ml. The third split was based on GRG status, followed by another split at a viral load of 55,500 copies/ml. The five groups
generated are color-coded and the number of subjects in each of these groups is shown along with their proportion in the study group. The values in
brackets ([ ]) indicate the relative hazard estimates corresponding to each of these groups as shown in Figure 2F. (B) Pie charts depicting the
proportion of subjects in each of the splits who did or did not develop AIDS (1987 criteria). Within each pie-chart, the dark pie-slice represents the
proportion of subjects who developed AIDS. Yes and no refers to whether a subject does or does not categorize, respectively, to the indicated node.
(C) KM plots for the rate of progression to AIDS from time of seroconversion based on the split at each corresponding node in the decision tree
shown in panel A. The significance values shown below each KM plot were estimated using the logrank test. (D–F) Association between the five risk
groups (panel D) generated by CART and the risk (panel E) and rate of developing AIDS (panel F). Panel D defines the risk groups based on the
baseline CD4 (cells/mm
3), steady state viral load (k,61,000 copies/ml), and GRG status (M/H, moderate or high GRG; Low, low GRG). Gp, group. Panel
E shows the probability (Prob) of developing AIDS within each risk group generated by CART analysis. ‘‘Overall’’ refers to the probability of
developing AIDS in the seroconverting component of the cohort without accounting for the laboratory or genetic markers. DP, change in probability
from the overall probability. Panel F shows the KM plots for rate of progression to AIDS for the five groups of subjects identified by CART. The table to
the right shows the relative hazards (RH) corresponding to these five groups estimated by using Cox proportional hazards models. In these analyses,
the reference category (RH=1) is group B, which denotes subjects that have a CD4 of $453 cells/mm
3 and a viral load of ,17,500 copies/ml. The
results show that relative to this reference category, groups A, C and E are associated with a significantly increased risk of progressing rapidly to AIDS.
(G–I) Similar analyses to those shown in panels D to F but using risk groups in which the GRGs are not included as prognosticators. In these analyses,
the risk groups A and B shown in panel A and panel D were used along with two new groups designated as group F and group G. The latter two
groups were derived from the Groups C to E shown in panel D by not accounting for the GRG status and dichotomizing the cohort further based on a
viral load cut-off of 55,500 copies/ml. Reference category (RH=1) is group B. In panels E and H, prob refers to probability.
doi:10.1371/journal.pone.0003165.g002
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stratified the cohort into five groups, denoted as groups A to E
(Figure 2A and Figure S1A). Interestingly, the most proximal node
defined by CART analysis was a CD4-cell count of 453 cells/
mm
3, which was similar to the CD4 cell count threshold we used
in the aforementioned analyses in risk-scoring systems (i.e.,
450 cells/mm
3, Figure 1A). Additional nodes included the GRG
and steady-state viral load of these subjects (Figure 2A and Figure
S1A). In this instance, the nodal split for viral load defined by
CART analysis was at 55,500 copies/ml, and this was similar to
the cut-off for viral load that we used in the analyses shown above
(i.e., 55,000 copies/ml; Tables 1 and 2 and Figure 1). The manner
in which these splits stratified subjects with variable risks of AIDS
development at each node is shown (Figure 2A and 2B).
To assess if the nodal splits derived based on differential risk of
AIDS development also conveyed differential rates of disease
progression, we plotted KM plots for each binary split shown in
the decision tree (Figure 2C). We observed that each nodal split
was also associated with statistically significant differences in the
rates of progression to AIDS (Figure 2C).
The five risk groups (Figure 2D) defined by the CART analysis
displayed strikingly different risks of future development of AIDS
(Figure 2E) as well as rates of disease progression (Figure 2F).
Compared to the pretest probability of developing AIDS in the
overall seroconverting component of the cohort (27%), Group C,
which is defined by individuals with a CD4 count of $453 cells/
mm
3, a viral load of $17,500 copies/ml, and moderate or high
GRG status, was associated with a 25% excess probability of
developing AIDS. By contrast, group B (subjects with a relatively
high baseline CD4 count ($453 cells/mm
3) and low steady-state
viral load (,17,500 copies/ml)) was associated with a 15% reduced
probability of developing AIDS in the future (Figure 2F). Cox
proportional hazards modeling demonstrated that Group C was
associated with the fastest rate of progression to AIDS, whereas
group B (subjects with a CD4 cell count of ,453453 cells/mm
3)w a s
associated the slowest rate of disease progression (Figure 2F).
To validate that GRG status provided additional predictive
value in the decision tree, we excluded GRG status from the
analysis, and determined the risk and rate of progressing to AIDS
for the four risk groups defined by the CD4 cell count and viral
load cut-offs generated by CART (Figure 2G). A comparison of
the identical analyses for the five (Figure 2D) versus four
(Figure 2G) risk groups revealed that inclusion of GRG status
within the stratification schema provided more a refined risk-
profile than a stratification schema that excluded GRG status
(compare Figure 2, E versus H and F versus I). The overall
discriminatory power for prognosticating subjects with differential
rates of progression to AIDS was improved by ,29% when the
GRGs were included for prognostication (P=0.0002; also
compare the log-rank x
2 values in the KM plots in Figure 2F
(x
2=60.35) and 2I (x
2=46.78), showing higher values when GRG
status is included in the model).
The analyses in Figure 2 are for the seroconverting component
of the WHMC HIV
+ cohort, and we replicated these observations
in the seroprevalent component of this cohort (Figure S2). Hence,
the findings of two distinct risk-stratification approaches (Figures 1
and 2, and Figure S2) in two large and separate groups of HIV
+
subjects demonstrated that the GRGs improve the ability to
capture the wide spectrum of AIDS risk. Remarkably, the CART
approach also showed that the CCL3L1-CCR5 GRGs assist in
AIDS prognosis mainly during early-stage disease, such as when
baseline CD4 cell counts are greater than 453 cells/mm
3, a CD4
cell count threshold that is well above the point at which ART is
currently recommended.
Criterion four
The aforementioned findings indicated that along with the CD4
cell count and viral load, the GRGs provided additive prognostica-
tion during the early stages of HIV infection, implying that the
GRGs might prognosticate the time-interval from seroconversion to
arrival at CD4 cell count thresholds relevant to commencing
therapy. Given the uncertainty surrounding the optimal time to
initiate HAART [7] as well as the results of our CART analysis, we
chose three CD4 cell count cut-offs to reflect early (450 to
approximate the 453 cut-off defined by CART analysis), interme-
diate (350), and late (200) HAART-initiating CD4 cell count
thresholds. These analyses revealed that there was a step-wise
increase inthe time-intervalfromseroconversion toarrival ateachof
these CD4 cell count thresholds in patients with a high, moderate
and low GRG (Figure 3A). Thus, it took nearly twice as long for
subjects with a low GRG status to arrive at a CD4 cell count
threshold of ,350 cells/mm
3 than subjects with a high GRG (5.48
vs 2.68 years; Figure 3A, middle).
Among seroconverting subjects who had ,450 CD4 cells/mm
3,
the mean CD4 cell counts did not differ according to a subjects’
GRG (mean in different GRGs was 375–383 cells/mm
3).
However, those with a low GRG status took nearly seven years
longer to progress from ,450 to ,200 cells/mm
3 than all other
subjects (Figure 3B). The difference in the rate of progression from
,450 to ,200 cells/mm
3 between those who were or were not
assigned to a low GRG remained significant even after adjustment
for the baseline CD4 cell count and viral load, the best DTH skin
test reactivity recorded during disease course, and cohort
membership in the calendar years 1990–1999, a time-period
during which most of the AIDS events in this cohort occurred and
HAART was available (Figure 3B, right).
Discussion
In this study, we tested the hypothesis that in conjunction with
laboratory markers currently used to assess AIDS risk, the complex
patterns of genetic variations in the human genome may have
utility as tools for improved risk assessment of patients infected
with HIV-1. The results of this study conducted in a large, and
well-characterized natural history cohort of HIV-infected individ-
uals indicate that in addition to the traditional markers of
vulnerability (baseline CD4+ T cell count, viral load and rate of
CD4
+ T cell decline), the inclusion of a measure of genetic risk
might offer an adjunctive, and complementary risk-stratification
tool that may provide an improved method for identifying persons
at high risk for future AIDS related events. These HIV vulnerable
individuals may be ideal candidates for preventive AIDS care such
as a closer follow-up, and potentially, earlier initiation of HAART.
This inference is based on the following four principal findings.
First, the predictive capacities of a low, moderate and high
GRG for risk of developing AIDS, as estimated by the likelihood
ratio, were equivalent to those of the strata of the laboratory
markers that were associated with a low-, moderate- and high-risk
of developing AIDS.
Second, although the GRGs and the viral load had similar
capacities for risk prognostication, GRG status was not a surrogate
marker for the viral load. Instead, GRG status by consistently
tracking individuals with reduced or increased likelihoods of
developing AIDS provided prognostic information even in those
instances when the laboratory markers predicted a contrary
likelihood of developing of AIDS. Thus, the GRGs provided
prognostic information with three unique characteristics, (i)
independence from the AIDS risk conveyed by the viral load
and CD4 cell count; (ii) equivalence in magnitude to the
CCL3L1-CCR5 in AIDS Prognosis
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in spite of contrary information imparted in some instances by the
viral load and CD4 cell count.
Third, the results from several complementary but distinct
approaches demonstrated that the genetic and laboratory markers
provide additive prognostic information that gauges the continuum
of the risk of AIDS and disease progression more accurately than
either marker alone. Importantly, the additive predictive capacity of
the GRGswas evident during the earlystages ofthe infection suchas
when the CD4 cell count was greater than 450 cells/mm
3.I ti s
especially noteworthy that in subjects with CD4$453 cells/mm
3
and viral load of $17,500 copies/ml (,15% of the study cohort), a
moderate or high GRG status was associated with a nearly seven-
fold increased risk of progressing rapidly to AIDS.
Fourth, CCL3L1-CCR5 GRG status served as an independent
determinant of how quickly HIV-infected subjects progressed to
thresholds of CD4 cell counts that are currently used to decide
when to initiate HAART. As a general rule, subjects with a
moderate or high GRG progressed to these HAART-initiating
CD4 cell count thresholds two to three times faster than those with
a low GRG.
Genetic risk stratification of HIV-infected patients is especially
attractive for three reasons. First, CCL3L1-CCR5 genotypes are not
only independent determinants of disease, but more importantly,
they are also capturing different aspects of AIDS risk than the
traditional components of AIDS risk reflected in the laboratory
markers currently used to assess disease status. Second, the time-
insensitive nature of the genetic markers and the capacity of the
GRGs to assess genetically-defined AIDS risk, especially during
the proximal stages of infection, is appealing because there is
substantial data suggesting that it is the magnitude of early
immune damage that dictates, in part, steady-state viral load,
Figure 3. CCL3L1-CCR5 GRGs influence median time-from-seroconversion to CD4 cell count thresholds that might be used to guide
initiation of HAART, and time from a high to a low CD4 cell count. In Panel A, KM plots show the time-from-seroconversion to arrival at ,450
(left), ,350 (center) or ,200 (right) CD-cells/mm
3. In Panel B, the KM plots are for progression from ,450 to ,200 CD4-cells/mm
3 in all
seroconverters (left) or seroconverters recruited and followed during the years 1990 to 1999, a time-period in which antiretroviral therapy was
available (right). The color codes for the KM plots in panel B are: blue, low GRG; brown, moderate and high GRGs combined into a single category;
and black, all subjects. Overall P values are at the top of each plot. Color-coded numbers at the upper right of the KM plots represent the median
time-to-event, that is, from seroconversion to the indicated CD4 cell count. In panel A, P values for differences in median time-to-event relative to
those with a low GRG were: *, 0.1131; {, 0.0089; {, 0.0030; 1, 0.0005; ", 0.0001; and I, 9.6610
27. RH, relative hazard; CI, confidence interval. P values in
Panel B are adjusted for the steady-state viral load, baseline CD4 and best DTH response recorded during disease course, and subjects with a
moderate or high GRG were combined into a single category.
doi:10.1371/journal.pone.0003165.g003
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+ loss, and subsequently, pace of HIV disease course
[20,26,65,66,67]. Third, the prevalence of the genetic factors that
we have identified in a U.S.-based cohort of HIV-positive
individuals (prevalence of the low, moderate and high GRGs is
,50, 42 and 8%, respectively) is large enough to be of clinical
relevance as these genetic factors can provide dual prognostica-
tion: risk of AIDS and disease progression, and recovery of CD4
cell numbers [23] and function [20] during HAART.
The robustness of the associations detected for CCL3L1-CCR5
GRG status is suggested by several observations. First, concordant
results were obtained when using different analytical approaches
and when using a stringent clinical phenotypic endpoint namely
AIDS (1987 CDC criteria). The finding that the copy number of
CCL3L1 and CCR5 genotypes together provided prognostication
during the early stages of the disease (CD4 cell counts of
.450 cells/mm
3) was detected using two separate approaches:
risk-scoring systems (Figure 1) and CART (Figure 2). Additionally,
consistent results for the latter two analyses were observed in two
separate groups of subjects from the same cohort (Table S1), both
of whom were followed prospectively from the early stages of their
infection [20]. Furthermore, concordant results were obtained
when the survival curves for the association between CCL3L1-
CCR5 GRGs were computed from either time-of-seroconversion
to different CD4 cell count thresholds (Figure 3A) or from one
CD4 cell count threshold to another (i.e., progression from ,450
to ,200 CD4-cells/mm
3; Figure 3B), and the latter associations
remained consistent after adjustment for other explanatory
variables known to influence disease progression rates.
One needs to be cognizant of an important point with regards to
the interpretation of our results. The genetic variations in CCR5
that affect HIV disease course differ in European and African
Americans [18,56], and the average copy number of CCL3L1
varies among populations [5]. Thus, we caution that as the genetic
information was derived from European and African American
HIV-positive subjects and because host-virus interactions are likely
to be highly population-specific, the composition of the GRGs
might vary depending on the study population. Despite this caveat,
it is noteworthy that the impact of CCL3L1 on HIV-AIDS
susceptibility has been observed in different geographic regions
([5,43,44,45,46] and unpublished observations), and that we and
others have found reproducible effects of specific CCR5 haplotype
pairs on disease progression rates (e.g. detrimental and beneficial
impact of the CCR5 HHE/HHE and HHC/HHG*2 genotypes,
respectively [15,17,18,19,39]). Illustrating a basis for the consis-
tency of the disease-influencing associations, these CCR5 haplo-
types are also associated with increased (CCR5-HHE) or decreased
(HHC or HHG*2) gene/protein expression of CCR5
[39,68,69,70,71], and of note, CCR5 density is in itself a
determinant of HIV susceptibility [69,72], viral load [73], disease
progression rates [74], and CD4 recovery during HAART
[75,76].
These findings also have value for improving our understanding
of the factors that influence HIV-AIDS pathogenesis and for the
interpretation of genotype-phenotype association studies in
general. The ability of the GRGs to provide an additive measure
of AIDS risk, including in those with high CD4 cell counts,
suggests that the impact of these host factors during chronic
infection is partly through viral load-independent mechanisms that
are likely operative in the proximal end of the causal pathways that
affect CD4 cell loss and establishment of the steady-state viral load.
This inference is consistent with those derived from the results our
previous studies where we suggested that a common CCL3L1-
CCR5 genetic pathway may regulate the balance between
pathogenic and reparative processes from the early stages of the
disease course [19,20,23]. These findings suggest that in addition
to their roles in HIV cell entry [1], CCR5 and its ligands may also
influence disease pathogenesis by impacting on parameters that
are not dependent on viral entry. This is consistent with the
observation that CCR5 and its ligands associate with a wide array
of immunological responses relevant to HIV-AIDS pathogenesis,
including cell-mediated immunity, T cell regeneration, activation-
induced cell death, and formation of the immunological synapse
[77,78,79,80,81,82,83,84,85,86,87,88,89,90]. However, it is likely
that the relative impact of these CCL3L1-CCR5-dependent
immune responses on HIV-AIDS pathogenesis may differ
depending on disease stage. Furthermore, the influence of
CCL3L1-CCR5 genotypes on HIV-AIDS pathogenesis is evident
at time of viral exposure (i.e., HIV acquisition) and soon after
seroconversion [5,20,23], and as shown herein, these genetic
factors provide independent prognostic information from the early
stages of the disease. Hence, from an epidemiological standpoint
the aforementioned observations suggest that genotype-phenotype
associations for CCL3L1 copy number and CCR5 genotype may
differ significantly depending on the characteristics and disease
stage of the subjects evaluated (e.g., those enrolled from the early
stages of their infection as part of a natural history cohort versus
accrual of subjects during the later stages of disease, or those
enrolled as part of a clinical trial, or selection of subjects based on
specific clinical or laboratory characteristics).
The notion that a large component of AIDS pathogenesis might
be conveyed by parameters that are independent of the viral load
is suggested by our previous findings where we found that steady-
state viral load and CCL3L1-CCR5 GRG status each explained
,9% and ,6%, respectively, of the variability in rate of
progression to AIDS [20]. The studies by Rodriguez et al also
underscore the notion that viral load only explains a small fraction
of the variability in the rate of decline in CD4
+ cell counts [91].
Thus, the finding that the CCL3L1-CCR5 GRGs influence AIDS
pathogenesis partly independent of the viral load suggests that
strategies to block viral load-independent pathways, such as those
linked to the CCL3L1-CCR5 axis, might provide a novel means to
curb CD4 cell loss during infection and aid immune reconstitu-
tion. Whether this can be accomplished with the current
generation of CCR5 blockers needs to be carefully evaluated
because studies with a small molecule CCR5 blocker [92] and a
CCR5 monoclonal antibody [93] suggest a beneficial effect of
blocking CCR5 on CD4
+ T cell recovery during HAART, in
instances when the prevailing viral strain is X4-tropic and
independent of viral load suppression, respectively.
In summary, we have conducted proof-of-concept analyses to
determine whether genetic information can be used to bring us
one step closer towards personalized HIV medicine. Using several
different approaches, in this prospective study of HIV-1 infected
individuals, the predictive capacity of CCL3L1- and CCR5-based
genetic risk stratification was not only independent of, but more
importantly, comparable to the prognostic information provided
by currently used predictors of AIDS risk. Thus, additional studies
will be required to determine whether in a manner analogous to
the use of HIV genotype, when applied judiciously along with
knowledge of the clinical and laboratory parameters, host
genotypes (e.g., CCL3L1-CCR5, HLA alleles) that associate with
different aspects of HIV disease pathogenesis, independent of CD4
cell count and viral load, might have practical utility in guiding the
care of infected individuals. Of broad relevance, using HIV as a
model system, we outline a series of analyses that might have
application to other diseases when assessing whether genetic
information can be used to improve the clinical care of patients
afflicted with these diseases.
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